Jazz Pharmaceuticals plc [JAZZ] stock is trading at $131.19, up 1.27%. An important factor to consider is whether the stock is rising or falling in short-term value. The JAZZ shares have gain 2.13% over the last week, with a monthly amount glided 10.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jazz Pharmaceuticals plc [NASDAQ: JAZZ] stock has seen the most recent analyst activity on July 15, 2025, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $152. Previously, UBS upgraded its rating to Buy on March 07, 2025, and elevated its price target to $179. On February 26, 2025, downgrade downgraded it’s rating to Neutral. Wells Fargo upgraded its rating to a Overweight and increased its price target to $170 on February 13, 2025. Morgan Stanley upgraded its rating to a Overweight and raised its price target to $175 on December 12, 2024. Goldman started tracking with a Buy rating for this stock on June 05, 2024, and assigned it a price target of $169. In a note dated January 03, 2024, Robert W. Baird initiated an Outperform rating and provided a target price of $160 on this stock.
Jazz Pharmaceuticals plc [JAZZ] stock has fluctuated between $95.49 and $148.06 over the past year. Currently, Wall Street analysts expect the stock to reach $167.75 within the next 12 months. Jazz Pharmaceuticals plc [NASDAQ: JAZZ] shares were valued at $131.19 at the most recent close of the market. An investor can expect a potential return of 27.87% based on the average JAZZ price forecast.
Analyzing the JAZZ fundamentals
Jazz Pharmaceuticals plc [NASDAQ:JAZZ] reported sales of 4.09B for the trailing twelve months, which represents a growth of 2.14%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.13%, and Net Profit Margin reading is -0.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.1 and Total Capital is -0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Jazz Pharmaceuticals plc’s Current Ratio is 1.62. On the other hand, the Quick Ratio is 1.37, and the Cash Ratio is 0.57. Considering the valuation of this stock, the price to sales ratio is 1.95, the price to book ratio is 2.15.
Transactions by insiders
Recent insider trading involved COZADD BRUCE C, Director, that happened on Sep 02 ’25 when 6000.0 shares were sold. Director, Winningham Rick E completed a deal on Aug 08 ’25 to buy 3731.0 shares. Meanwhile, Director Kennedy Patrick bought 3731.0 shares on Aug 08 ’25.
